Drugs / Linaprazan
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05742984 | Jan → Mar 2023 | gastroesophageal reflux disease | Cinclus Pharma Holding AB | Completed | No outcome recorded |
| Phase 1 | NCT05633147 | Nov 2022 → May 2023 | — | Cinclus Pharma Holding AB | Completed | No outcome recorded |
| Phase 1 | NCT05627518 | Nov → Dec 2022 | — | Cinclus Pharma Holding AB | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00206245 | May 2004 → Mar 2005 | esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00206284 | May 2004 → Apr 2005 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07313774 | Mar 2026 → Sep 2028 | gastroesophageal reflux disease | Cinclus Pharma Holding AB | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT07037875 | Sep 2025 → Aug 2026 overdue | gastroesophageal reflux disease | Cinclus Pharma Holding AB | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-04 | Cinclus Pharma Holding AB | Results Cinclus Pharma announces positive topline results from the LEED phase II eGERD study cincluspharma.com ↗
For patients with moderate to severe eGERD, LA grade C/D, the highest four-week healing rate in a linaprazan glurate dosing group was 89%, compared to 38% in the lansoprazole group. |
All press releases naming this drug 14 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Linaprazan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05742984 ↗ |
| Known as | AZD0865 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00206284 ↗ |
| Modality | Small molecule | — CHEMBL497011 ↗ |
| Route | Oral | “Treatment With AZD0865 25, 50, 75 mg and Esomeprazole 40 mg, Given Orally Once Daily” NCT00206245 ↗ |